Promising new combo aims to prevent deadly transplant complication
NCT ID NCT02891603
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This study tested a new drug combination (pacritinib, sirolimus, and tacrolimus) to prevent graft-versus-host disease (GVHD) in 40 blood cancer patients receiving a stem cell transplant from a matched donor. GVHD is a serious condition where donor cells attack the patient's body. The goal was to see if this approach is safe and reduces GVHD risk. Participants were monitored for side effects and signs of GVHD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.